

Global Epigenomic Analysis of Primary Human Pancreatic Islets Provides Insights into Type 2 Diabetes Susceptibility Loci

Michael L. Stitzel, Praveen Sethupathy, Daniel S. Pearson, Peter S. Chines, Lingyun Song, Michael R. Erdos, Ryan Welch, Stephen C.J. Parker, Alan P. Boyle, Laura J. Scott, NISC Comparative Sequencing Program, Elliott H. Margulies, Michael Boehnke, Terrence S. Furey, Gregory E. Crawford, and Francis S. Collins*

*Correspondence: collinsf@mail.nih.gov

DOI [10.1016/j.cmet.2010.11.013](https://doi.org/10.1016/j.cmet.2010.11.013)

(Cell Metabolism 12, 443–455; November 3, 2010)

In the preparation of this article, we made two typographical errors that we wish to correct:

- (1) The right promoter (marked by the right red box) in Figure 3B is incorrectly labeled. The correct label is: “Annotated islet-active promoter.”
- (2) The second sentence of the third paragraph in the Discussion section is incorrect. The corrected sentence is: “Focusing on T2D, 4 of the 12 elements that function as enhancers in vitro (*FTO*, *KCNQ1*, *TCF7L2*, and *WFS1* loci) harbor T2D-associated SNPs, including two (*TCF7L2* and *WFS1* loci) that exhibit significant allele-specific differences in activity.”

This correction does not affect the data or the conclusions of the paper, and we apologize for any confusion the errors may have caused.